Rufinamide is a triazole derivative, a compound structurally distinct from currently approved AEDs. In a multicenter, double-blind, placebo-controlled clinical trial, rufinamide was shown to have clinical benefit in the treatment of seizures associated with LGS and was designated as an orphan drug for this indication by the FDA in October 2004.
This member assumes full responsibility for the content of this listing. DIYTrade accepts no responsibility whatsoever in respect of such content. To report fraudulent or illegal content, please click here.